ClinVar Miner

Submissions for variant NM_000642.3(AGL):c.664+3A>G

gnomAD frequency: 0.00001  dbSNP: rs370792293
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000169374 SCV000220754 likely pathogenic Glycogen storage disease type III 2014-09-30 criteria provided, single submitter literature only
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000585987 SCV000697535 pathogenic Glycogen storage disease IIIa 2017-04-21 criteria provided, single submitter clinical testing Variant summary: The AGL c.664+3A>G variant is an intronic change that involves a conserved nucleotide. 3/5 splice prediction tools predict an impact on normal splicing, which was confirmed by Lucchiar_2002. The cDNA analysis revealed found an in-frame deletion of exon 6 caused by the variant of interest, and, as confirmation, all homozygous patients showed no enzymatic residual activity. This variant was found in 2/120192 control chromosomes at a frequency of 0.0000166, which does not exceed the estimated maximal expected allele frequency of a pathogenic AGL variant (0.0022822). The variant was identified in multiple GSD III patients homozygously or in compound heterozygosity. Lastly, a clinical diagnostic laboratory classifies the variant as "likely pathogenic." Taking together, the variant of interest has been classified as "pathogenic."
Invitae RCV000169374 SCV001382430 pathogenic Glycogen storage disease type III 2024-01-24 criteria provided, single submitter clinical testing This sequence change falls in intron 5 of the AGL gene. It does not directly change the encoded amino acid sequence of the AGL protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product. This variant is present in population databases (rs370792293, gnomAD 0.002%). This variant has been observed in individual(s) with glycogen storage disease type III (PMID: 12442284, 16705713, 21691223). This variant is also known as IVS6 +3 A>G. ClinVar contains an entry for this variant (Variation ID: 188994). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 5 (also known as exon 6), but is expected to preserve the integrity of the reading-frame (PMID: 12442284). For these reasons, this variant has been classified as Pathogenic.
Genome-Nilou Lab RCV000169374 SCV002055470 likely pathogenic Glycogen storage disease type III 2021-07-15 criteria provided, single submitter clinical testing
Genomic Research Center, Shahid Beheshti University of Medical Sciences RCV000169374 SCV004171066 pathogenic Glycogen storage disease type III 2023-11-26 criteria provided, single submitter clinical testing
Baylor Genetics RCV000169374 SCV004211046 pathogenic Glycogen storage disease type III 2023-09-09 criteria provided, single submitter clinical testing
Division of Human Genetics, Children's Hospital of Philadelphia RCV000169374 SCV000536700 likely pathogenic Glycogen storage disease type III 2014-10-31 no assertion criteria provided research
Natera, Inc. RCV000169374 SCV001454498 pathogenic Glycogen storage disease type III 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.